News & Updates

Faricimab outclasses aflibercept in treatment of nAMD

11 May 2025

In adult patients with treatment-naive neovascular age-related macular degeneration (nAMD), the use of faricimab shows superior anatomic outcome compared with aflibercept during the head-to-head dosing phase, reports a study.

Faricimab outclasses aflibercept in treatment of nAMD

11 May 2025

Dexamethasone trumps MTX, ranibizumab in treatment of macular oedema

10 May 2025

A recent study has found that dexamethasone delivers better outcomes than methotrexate (MTX) and ranibizumab in patients with persistent or recurrent uveitic macular oedema through 24 weeks. In addition, side effects are manageable.

Dexamethasone trumps MTX, ranibizumab in treatment of macular oedema

10 May 2025

Gradual adalimumab tapering minimizes uveitis recurrence in children

15 Apr 2025

In children with noninfectious uveitis being treated with adalimumab, tapering speed appears to affect the risk of relapse, with a slow, gradual approach emerging as the optimal strategy, according to a multicentre retrospective cohort study.

Gradual adalimumab tapering minimizes uveitis recurrence in children

15 Apr 2025

Early-onset AD implicated in paediatric uveitis

10 Apr 2025

Children with early-onset atopic dermatitis (AD) face an increased risk of uveitis, as reported in a study.

Early-onset AD implicated in paediatric uveitis

10 Apr 2025

Eyebrow or eyelash hair loss affects QoL in AA patients

25 Mar 2025 by

A real-world analysis presented at AAD 2025 shows that patients with alopecia areata (AA) with eyebrow or eyelash hair loss have greater health-related quality of life (HRQoL) burden than those without eyebrow and eyelash involvement.

Eyebrow or eyelash hair loss affects QoL in AA patients

25 Mar 2025

Prior intravitreal injection tied to complications following cataract surgery

23 Mar 2025

Complications following cataract surgery appear to be more frequent among patients with prior intravitreal injection (IVI) therapy than among those without, as shown in a retrospective study.

Prior intravitreal injection tied to complications following cataract surgery

23 Mar 2025

GLP-1 RAs lower POAG, ocular hypertension risks in T2D patients

17 Mar 2025

The use of glucagon-like peptide 1 receptor agonists (GLP-1 RA), compared with metformin, results in a significant decrease in the incidence of primary open-angle glaucoma (POAG), ocular hypertension, and the need for first-line glaucoma treatments in patients with type 2 diabetes (T2D), reports a study.

GLP-1 RAs lower POAG, ocular hypertension risks in T2D patients

17 Mar 2025

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

04 Mar 2025 by

Two-year treatment with brolucizumab 6 mg every 4 weeks demonstrates noninferiority in mean best-corrected visual acuity (BCVA), with superior anatomic outcomes, to aflibercept 2 mg every 4 weeks in patients with neovascular age-related macular degeneration (nAMD), as shown in the MERLIN study.

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

04 Mar 2025

Lung function a potential biomarker for glaucoma

28 Feb 2025 by

Lung function measures are associated with risk of glaucoma, indicating their potential role as biomarkers for the optic neuropathy with a devastating visual impact, researchers from the Chinese University of Hong Kong, Princes of Wales Hospital and Hong Kong Eye Hospital have reported.

Lung function a potential biomarker for glaucoma

28 Feb 2025

Semaglutide linked to modest increase in risk of nonarteritic anterior ischemic optic neuropathy

27 Feb 2025

The use of semaglutide among individuals with type 2 diabetes (T2D) appears to carry a modest increase in the risk nonarteritic anterior ischemic optic neuropathy (NAION), according to a retrospective study.

Semaglutide linked to modest increase in risk of nonarteritic anterior ischemic optic neuropathy

27 Feb 2025

News & Updates

Filter by Specialty:

Specialty:

Faricimab outclasses aflibercept in treatment of nAMD

Faricimab outclasses aflibercept in treatment of nAMD

Dexamethasone trumps MTX, ranibizumab in treatment of macular oedema

Dexamethasone trumps MTX, ranibizumab in treatment of macular oedema

Gradual adalimumab tapering minimizes uveitis recurrence in children

Gradual adalimumab tapering minimizes uveitis recurrence in children

Early-onset AD implicated in paediatric uveitis

Early-onset AD implicated in paediatric uveitis

Eyebrow or eyelash hair loss affects QoL in AA patients

Eyebrow or eyelash hair loss affects QoL in AA patients

Prior intravitreal injection tied to complications following cataract surgery

Prior intravitreal injection tied to complications following cataract surgery

GLP-1 RAs lower POAG, ocular hypertension risks in T2D patients

GLP-1 RAs lower POAG, ocular hypertension risks in T2D patients

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

Lung function a potential biomarker for glaucoma

Lung function a potential biomarker for glaucoma

Semaglutide linked to modest increase in risk of nonarteritic anterior ischemic optic neuropathy

Semaglutide linked to modest increase in risk of nonarteritic anterior ischemic optic neuropathy